FILTER
FILTERED INTERVIEW RESULTS
Candice Long
PRESIDENT – US INFECTIOUS DISEASES & VACCINES, JANSSEN PHARMACEUTICALS
"In vaccines, we are progressing late-stage programs of break-through vaccines against diseases where vaccines are not currently available, such as RSV and multidrug resistant bacterial infections, including ExPEC and Staphylococcus aureus."
Joe Panetta
PRESIDENT & CEO, BIOCOM CALIFORNIA
"We experienced explosive growth across the state and consequently adopted a new name: Biocom California."
John Pennett
PARTNER-IN-CHARGE OF THE NATIONAL TECHNOLOGY AND LIFE SCIENCES GROUP, EISNERAMPER
EisnerAmper speaks about the investment climate for pharma entrepreneurs.
Swapan Bhattacharya
MANAGING DIRECTOR, TCG LIFESCIENCES
TCG Lifesciences explains its discovery engine aimed to build out a large portfolio of new chemical entities that can one day become marketed drugs
Rich Christie
CHIEF MEDICAL OFFICER, AICURE
Aicure explains how Artificial Intelligence and virtual communications with patients can make healthcare more effective.
Steve Tallant
DIRECTOR, MARKET DEVELOPMENT, MARKEM-IMAJE
Systech helps pharma companies with serialization and compliance with DSCSA.
Paul Smaltz
VP GLOBAL BUSINESS UNIT PHARMACEUTICALS, ROQUETTE
Roquette describes how it is expanding in the US.
Trevor Martin
CO-FOUNDER & CEO, MAMMOTH BIOSCIENCES
"Ultimately, we aim to fine-tune this foundational technology that can be applied to innumerable challenges across a variety of industries, making biology become more like software and programming."
Alan Petro
CEO, NEW VISION PHARMACEUTICALS
"We had a client approach us to work on a rapid Covid test, wanting to produce a single-use vial for at-home testing. It was only six weeks between when we had our initial discussion to when we had produced the product for them."
Lars Schneider
PRESIDENT OF BRENNTAG SPECIALTIES, AMERICAS– BRENNTAG NORTH AMERICA, INC
"Project Brenntag and our supply chain capabilities have certainly supported us, providing a clear focus between our different businesses and specializations to grow in the pharma and life science markets."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
